Latest News and Press Releases

Company presented clinical and preclinical data at the MDA Conference last week in Dallas, TexasOral presentation included data from MuSK-MG rat model depicting increases in muscle function and...

Company presented clinical and preclinical data at the MDA Conference last week in Dallas, TexasOral presentation included data from MuSK-MG rat model depicting increases in muscle function and...

Aarhus, Denmark, 19 December 2024 – NMD Pharma A/S, a clinical-stage biotech company dedicated to developing novel and improved treatments for patients living with neuromuscular diseases, today...

Aarhus, Denmark, 19 December 2024 – NMD Pharma A/S, a clinical-stage biotech company dedicated to developing novel and improved treatments for patients living with neuromuscular diseases, today...

NMD Pharma Receives IND Clearance from the FDA to initiate a Phase 2 Clinical Trial of NMD670 in Charcot-Marie-Tooth disease in the US Aarhus, Denmark, 18 June 2024 – NMD Pharma A/S, a clinical-stage...

NMD Pharma Receives IND Clearance from the FDA to initiate a Phase 2 Clinical Trial of NMD670 in Charcot-Marie-Tooth disease in the US Aarhus, Denmark, 18 June 2024 – NMD Pharma A/S, a clinical-stage...

Mike Heffernan appointed Chairman of NMD Pharma’s Board of Directors Brings 30 years of experience building private and public development-stage and commercial biopharmaceutical companies and has...

Mike Heffernan appointed Chairman of NMD Pharma’s Board of Directors Brings 30 years of experience building private and public development-stage and commercial biopharmaceutical companies and has...

PRESS RELEASE NMD Pharma expands its US presence Creates US subsidiary and increases US R&D and staff recruitment activity Aarhus, Denmark, 3 May 2022 – NMD Pharma A/S, a clinical stage biotech...

NMD Pharma Doses the First Myasthenia Gravis Patient in a Combined Phase I/IIa Clinical Trial of NMD670 Aarhus, Denmark, 30 June 2021 – NMD Pharma A/S, a biotech company leading in the development...